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Andrew S. Wechsler, MD 
n this issue of the Journal, Sawa and his colleagues 
present a well-conceptualized xperiment. Using 
an inactivated viral transmitter, they successfully 
transfect intact hearts and demonstrate localization 
of genomic material in the nucleus, cytoplasmic 
expression of a gene product, and physiologic activ- 
ity attributable to an overexpressed protein that is 
presumably the consequence of enhanced transcrip- 
tion (pretranslational control). Several facets of this 
study are worthy of comment. 
The role of molecular biology in cardiac physiol- 
ogy and, more specifically, cardiac surgery has been 
evolving. Initially, molecular biologic techniques 
were used for diagnostic purposes to determine the 
appearance of new or altered gene products in 
abnormal myocardium. Thus our knowledge of al- 
tered proteins in cardiomyopathy, the existence of 
tiny amounts of neurotransmitters, and the down- 
regulation or discoordinate regulation of messen- 
gers for specific proteins have all been enhanced. 
Other studies took advantage of modifiers of gene 
expression to produce abnormal growth in cardiac 
cells by manipulation of promoters or enhancers (or 
both) of normally expressed genes. Such studies 
were most effective in transgenic animals. Other 
transgenic models have been used to demonstrate 
the effect of eliminating a gene product or overex- 
pressing a particular product such as the ¢3-receptor 
to demonstrate he physiologic role of those cellular 
elements. Such studies may ultimately lead to cre- 
ating chimeras that may facilitate xenotransplanta- 
tion through modification of surface antigens. 
Real-time modulation of gene expression for a 
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useful physiologic purpose has been slow in coming, 
and for good reason. Oligonucleotides capable of 
serving as the template for subsequent message and 
protein synthesis have been introduced into cardiac 
cells by direct injection or by infusion into the 
coronary circulation, but with such a low expression 
rate that major transformation ofmyocytes has been 
disappointing. Viral vectors introduced into the 
cardiac circulation have appeared to be the most 
promising method for achieving high transfection 
rates. In this study, two unique features have been 
combined. First, the infective capsule of an inacti- 
vated hemagglutinating virus has been coupled me- 
chanically into a liposomal structure. Second, by 
perfusion of the coronary circulation with this trans- 
ducing agent, an extraordinarily high level of expres- 
sion of the protein product resulted. Presumably, 
alteration of the cell membrane by cold, isolation of 
the coronary circulation, and structural properties of 
the viral capsule facilitated transfection. Although 
the number of animals studied was small, the most 
exciting aspect of these studies was that a physio- 
logic effect of the overexpressed protein (manga- 
nese-superoxide ismutase) could be demonstrated 
vis-a-vis preservation of ventricular performance 
after a period of ischemia and reperfusion. The 
study design was complex, the potential for system- 
atic error was high, and test conditions were difficult. 
Nonetheless, preserved ventricular function was 
demonstrated in association with Western block 
confirmation of increased enzyme levels. 
Will these studies lead to any practical therapies? 
At least two methods of myocardial protection have 
been linked to enhanced expression of gene prod- 
ucts. Heat shock protein appears to be an effective 
myocardial protective agent when overexpressed in 
myocytes, and overexpression f protein kinase in- 
duced by phorbol esters may play an important role 
in preconditioning. However, the delay between the 
genetic stimulus and expression of the protein prod- 
uct retards a practical approach to enhancing myo- 
cardial protection. Transfection of myocytes i asso- 
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ciated with ,other concerns as well. Viral vectors 
mediate inflammatory responses within the myocar- 
dium and could prove detrimental in the long term 
or even incite autoimmune responses. The duration 
of expression of new gene products may be very 
short lived. Genomic material in the cytoplasm is 
rapidly destroyed. Genomic material that migrates 
into the nucleus of somatic cells is usually not 
replenished and has an effect hat disappears after a 
few weeks. New genetic material is usually intro- 
duced without he benefit of specific regulators of its 
biochemical :[unction, and normal physiologic mech- 
anisms for controlling expression of these products 
is absent. Routinely high transfection rates may be 
difficult to achieve in settings other than those that 
modify cell membrane integrity. 
The next decade will be of great importance in 
determining the practicality of these interventions. 
Exciting potential applications of gene therapy 
might include normalization of abnormal contractile 
proteins in cardiomyopathies, rapid induction of cell 
hypertrophy in association with corrective opera- 
tions that stress nonhypertrophied cardiac cham- 
bers, induction of proteins that could protect against 
intracellular oxidant stress, and facilitating recovery 
from ischemic injury by inducing overexpression f 
important cellular elements down-regulated in asso- 
ciation with ischemia and reperfusion. The fantasy 
of inducing new myocyte growth as the controls in 
embryogenesis are better understood exists, as does 
the notion of regenerating cardiac tissue on struc- 
tural matrices. Surface antigen modification may 
facilitate transplantation. Such interventions are a 
long trip from the observations made by Sawa and 
his colleagues, but the impetus to take the first steps 
certainly exists. 
